RICHMOND, Va. — Haleon, a global company behind home healthcare products like Advil, Tums and Aquafresh, announced Monday its plan to upgrade its Richmond research and development facility.

The UK-based pharmaceutical company Haleon will invest $54.2 million to upgrade its R&D facility in Richmond, which has helped birth or grow products such as Advil, Emergen-C and Robitussin.

Pfizer has sold 700 million shares in British consumer-healthcare business Haleon for 2.50 billion pounds, equivalent to US$3.05 billion, it said in a statement. The U.S. drugmaker said Wednesday ...

Once complete, Pfizer's stake in Haleon will fall from 15.0% to around 7.3%. Pfizer's move comes after Haleon's spin-off as an independent consumer healthcare company, part of plans to reshape its ...

Pfizer (PFE) announces that it intends to sell approximately 700M ordinary shares in Haleon plc (HLN), representing approximately 7.7% of Haleon’s issued share capital. “There will be no sale ...

Shares of Haleon PLC HLN inched up 0.97% to £3.73 Friday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 1.35% to 8,505.22.

Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon , lowering its stake ... second-quarter profit was hit by one-time charges related to its joint venture with Nestle ...

GSK’s consumer health spinout Haleon has acquired exclusive US rights ... “This agreement, with one of the world’s leading global consumer healthcare companies, represents a major milestone ...

Haleon Plc engages in the provision of personal healthcare products. The firm focuses on consumer healthcare. It operates under the following geographical segments: North America, EMEA and LatAm ...

Once complete, Pfizer's stake in Haleon will fall from 15.0% to around 7.3%. Pfizer's move comes after Haleon's spin-off as an independent consumer healthcare company, part of plans to reshape its ...